Abstract:In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18–40 (n = 129), 40–60 (n = 62) and 60–90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands’ power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.

A holo-spectral EEG analysis provides an early detection of cognitive decline and predicts the progression to Alzheimer's disease

EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer's disease

Neural Biomarker Diagnosis and Prediction to Mild Cognitive Impairment and Alzheimer’s Disease Using EEG Technology

Early Detection of Alzheimer’s Disease Using Non-invasive Near-Infrared Spectroscopy

Fully Automated Discrimination of Alzheimer's Disease Using Resting-State Electroencephalography Signals.

Resting EEG Discrimination of Early Stage Alzheimer’s Disease from Normal Aging Using Inter-Channel Coherence Network Graphs

Spectral and complexity analysis of scalp EEG characteristics for mild cognitive impairment and early Alzheimer's disease

EEG-Based Classification Between Individuals with Mild Cognitive Impairment and Healthy Controls Using Conformal Kernel-Based Fuzzy Support Vector Machine

Electroencephalography-based classification of Alzheimer's disease spectrum during computer-based cognitive testing

Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia

Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment

Resting State Eeg Multiscale Entropy Dynamics in Mild Cognitive Impairment and Early Alzheimer'S Disease

Resting-state electroencephalographic characteristics related to mild cognitive impairments

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage

Mild Cognitive Impairment detection based on EEG and HRV data

Resting State Electroencephalography Contributes to the Detection of Disease Progression and Prediction of Repetitive Transcranial Magnetic Stimulation Modulations in Patients with Subjective Cognitive Decline

Discrimination of Mild Cognitive Impairment and Alzheimer's Disease Using Transfer Entropy Measures of Scalp EEG.

Cognitive Function Assessment and Prediction for Subjective Cognitive Decline and Mild Cognitive Impairment.

Screening and predicting progression from high-risk mild cognitive impairment to Alzheimer’s disease

PROGNOSIS OF CONVERSION TO MILD COGNITIVE IMPAIRMENT AND TIME TO STABLE CHANGES VIA MEMORY-RELATED ELECTROPHYSIOLOGICAL BRAIN SIGNATURES

Multiple Cross-Frequency Coupling Analysis of Resting-State EEG in Patients with Mild Cognitive Impairment and Alzheimer's Disease.